Your browser doesn't support javascript.
loading
Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors.
Rogers, Thomas F; Goodwin, Eileen C; Briney, Bryan; Sok, Devin; Beutler, Nathan; Strubel, Alexander; Nedellec, Rebecca; Le, Khoa; Brown, Michael E; Burton, Dennis R; Walker, Laura M.
Afiliação
  • Rogers TF; Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA.
  • Goodwin EC; Adimab LLC, Lebanon, NH 03766, USA.
  • Briney B; Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA.
  • Sok D; Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA.
  • Beutler N; Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA.
  • Strubel A; Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA.
  • Nedellec R; Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA.
  • Le K; Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA.
  • Brown ME; Adimab LLC, Lebanon, NH 03766, USA.
  • Burton DR; Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA. laura.walker@adimab.com burton@scripps.edu.
  • Walker LM; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Sci Immunol ; 2(14)2017 Aug 18.
Article em En | MEDLINE | ID: mdl-28821561
ABSTRACT
Zika virus (ZIKV) shares a high degree of homology with dengue virus (DENV), suggesting that preexisting immunity to DENV could affect immune responses to ZIKV. We have tracked the evolution of ZIKV-induced B cell responses in three DENV-experienced donors. The acute antibody (plasmablast) responses were characterized by relatively high somatic hypermutation and a bias toward DENV binding and neutralization, implying the early activation of DENV clones. A DENV-naïve donor in contrast showed a classical primary plasmablast response. Five months after infection, the DENV-experienced donors developed potent type-specific ZIKV neutralizing antibody responses in addition to DENV cross-reactive responses. Because cross-reactive responses were poorly neutralizing and associated with enhanced ZIKV infection in vitro, preexisting DENV immunity could negatively affect protective antibody responses to ZIKV. The observed effects are epitope-dependent, suggesting that a ZIKV vaccine should be carefully designed for DENV-seropositive populations.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article